ALEGENT HEALTH – Trademark Portfolio
Entity Type: 03
ALEGENT HEALTH holds 34 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 19 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include EFOCUS. The owner is based in Omaha, NE.
12809 West Dodge Road
Omaha, NE 68154
Showing of trademarks Trademarks
Trademark Classifications
ALEGENT HEALTH's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Education; providing of training; entertainment; sporting and cultural activities
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does ALEGENT HEALTH have?
ALEGENT HEALTH has 34 U.S. trademarks filed with the USPTO. Of these, 1 registered, 14 abandoned, 19 cancelled.
What trademark classes does ALEGENT HEALTH file in?
ALEGENT HEALTH files trademarks across 4 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are ALEGENT HEALTH's most well-known trademarks?
ALEGENT HEALTH's registered trademark portfolio includes well-known marks such as EFOCUS. These are among 1 currently registered trademark in the portfolio.
What is ALEGENT HEALTH's trademark registration success rate?
ALEGENT HEALTH has a 3% trademark registration rate, with 1 out of 34 resolved applications resulting in successful registration. Currently, 0 applications are pending review.